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a b s t r a c t
West syndrome is the most frequent cause of epilepsy in Down syndrome. West synd-
rome is often associated with poor long-term prognosis in most of children. We report
a girl with West syndrome associated with Down syndrome which occurred at 8 months
of age for repetitive ﬂexor spasms and electroencephalography (EEG) showed hypsarr-
hythmia. She had Down syndrome facies, microcephaly, psychomotor development
delay and axial hypotonia. Computed tomography of the brain was normal. Her karyo-
type was 47, XX, +21. Phenobarbital therapy was immediately effective with good clinical
control of seizures, while the EEG monitored after one month was unchanged. At 2 years
of age, the patient had hypertonic status epilepticus following a lung infection. The EEG
showed a persistence of hypsarrhythmia. Sodium valproate and hydrocortisone therapy
was effective with good seizure control but her psychomotor development was severely
impaired. After a follow-up of 7 years, the patient presents growth retardation, microcep-
haly, severe psychomotor development delay, generalized hypotonia and tetraparesis.
Knowledge of West syndrome in Down syndrome allows the early detection and prompt
management of this neurological complication in order to optimize psychomotor deve-
lopment and improve the quality of life of these children.
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West syndrome or infantile spasms are a rare form of severe
epilepsy, described for the ﬁrst time by West in 1841.
Epileptic spasms must be associated with a psychomotor
regression and electroencephalography (EEG) hypsarythmia* Corresponding author at: Department of Pediatrics and Neonatology
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known that the incidence of major forms of epilepsy is
higher in children with Down syndrome than in the general
population, and West syndrome is the most frequent and
most severe form of epilepsy in these children [3, 4].
In the general population of children, the incidence of
West syndrome ranges from 2.2 to 4.5 per 10 000 live births, Tahar Sfar University Hospital, 5111 Mahdia, Tunisia.
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with Down syndrome. It has been reported that 6.4 to 8.1%
of patients with Down syndrome had epilepsy, and 12.8–32%
of these epileptic patients with Down syndrome had West
syndrome [2, 7]. The West syndrome begins during the ﬁrst
year of life in 90% of those affected children. The peak age
of onset is usually between 3 and 7 months. However, onset
after 18 months is rare, though onset up to 4 years of age
has been reported [8].
The association of infantile spasms with Down syndrome
is considered a symptomatic form because of preexisting
psychomotor development delay. However, the prognosis
seems to be better in this association than in cryptogenic
forms. This prognosis is linked to early diagnosis and rapid
initiation of adequate treatment, but the long-term progno-
sis is often very poor in most of these children [1, 4]. We
report a case of West syndrome in a girl with Down
syndrome and we discuss the clinical characteristics, mana-
gement and prognosis of this association.
Case report
An 8-month-old girl developed repetitive ﬂexor spasms
associated with fever, and was referred to the department of
pediatrics. She was the ﬁrst child of healthy non-consangui-
neous parents. Her mother was 46-year-old, and pregnancy
was not followed. She was born at term with vaginal delivery
without incident and neonatal period was unremarkable. Her
psychomotor development was abnormal with hypotonia and
disability of head control. At 8 months, she had ﬂexor spasms
several times a day, occurring in series. At admission, she
was fever to 38.4 8C, Down syndrome facies, microcephaly,
short neck with skin folds, brachydactyly and single crease in
the palm, psychomotor development delay and axial hypoto-
nia. The following laboratory tests were normal: complete
blood counts, serum chemistry results, and serum electroly-
tes. The fever was linked to a viral infection, but no viral
studies were performed. The thyroid function was normal.
The transfontanellar ultrasound was normal. Computed
tomography of the brain did not demonstrate any abnormali-
ties. The karyotype showed 47, XX, +21. The initial EEG
showed hypsarrhythmia and she was diagnosed as having
Down syndrome associated with West syndrome. She was
treated with phenobarbital before the result of EEG at a dose
of 3 mg/kg/day and her seizures disappeared immediately
with good control of these seizures for 16 months, while the
EEG monitored after one month of admission was unchanged.
At 2 years of age, the patient was readmitted for hyperto-
nic status epilepticus following a lung infection. The EEG
showed a persistence of hypsarrhythmia. Thus, she was
treated with Sodium valproate at a dose of 30 mg/kg/day and
hydrocortisone at a dose of 2 mg/kg/day and her seizures
disappeared immediately. Thereafter, hydrocortisone was
stopped after 3 months and sodium valproate was continued
at the same dose. At long-term, valproate therapy was
effective with good seizure control but her psychomotor
development was severely impaired. After a follow-up of
7 years, the patient presents growth retardation, microcep-
haly, severe psychomotor development delay, generalizedhypotonia, tetraparesis and epilepsy well controlled by
sodium valproate.
Discussion
Down syndrome is the most common genetic cause of
mental retardation with a reported prevalence of epilepsy of
6.4–8.1%. Infantile spasms or West syndrome is the most
frequent epilepsy syndrome in children with Down synd-
rome. West syndrome occurs in 0.6–13% of children with
Down syndrome, representing 12.8–32% of seizures in these
children [2, 7].
The mechanisms that raise susceptibility to infantile
spasms in patients with Down syndrome have yet to be
thoroughly uncovered. However, several authors suggest
a potential epileptogenic role for the interaction of various
Down syndrome-speciﬁc structural abnormalities of the
brain, such as lower rates of inhibitory interneurons, decrea-
sed neuronal density, abnormal neuronal lamination, persis-
tence of dendrites with fetal morphology, primitive synaptic
proﬁles or altered membrane potassium permeability [1, 2].
The diagnosis of West syndrome is often easy when the
infantile spasms are associated with arrest or regression of
psychomotor development, and a speciﬁc EEG pattern of
hypsarrhythmia [1, 5]. The clinical symptoms of infantile
spasms are very different than any other type of seizure
because of the absence of paroxysmal motor phenomena,
such as convulsions or loss of consciousness. This lack of
more typical of seizure phenomena may lead to initial
misdiagnosis of infantile spasms by pediatricians at the ﬁrst
medical consultation. Recently, it was reported that approxi-
mately one third of infants with infantile spasms were not
suspected of having epilepsy during the ﬁrst medical consul-
tation [9, 10]. Infantile spasms in infants are usually symme-
trical and manifested by a repetitive ﬂexor, extensor or ﬂexor–
extensor spasms with sudden and brief axial contraction,
predominating in the upper limbs, with upper deviation of
the eyes [11].
It is estimated that approximately 60–90% of children with
West syndrome have an associated with a brain abnormality
such as brain injury or cortical and subcortical malformations
of the brain due to abnormal development, present in isola-
tion or associated with other diseases such as Down synd-
rome [8, 12]. The magnetic resonance imaging is required to
study the brain with great precision and detect brain malfor-
mations in some children [12]. In our case, the computed
tomography of the brain did not demonstrate any abnormali-
ties but magnetic resonance imaging of brain has not been
made because this magnetic resonance imaging is not avai-
lable in our hospital and parents do not have the means.
Medical treatment of infantile spasms should be effective
and initiated as early as possible. Evaluation of treatment
effectiveness includes cessation of spasms, a resolution of
hypsarrhythmia on the EEG and reduction the cognitive
decline associated with epilepsy. Currently, vigabatrin and
adrenocorticotropic hormone (ACTH) are the only drugs
whose effectiveness was approved to suppress clinical
spasms and abolish the hypsarrhythmia on the EEG. In the
literature, different treatment protocols were used, but the
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vigabatrin as ﬁrst line treatment and ACTH as second line
treatment [8, 13, 14].
The vigabatrin dose should begin at 50 mg/kg/day and be
escalated up to 100–150 mg/kg/day in those patients requiring
escalation. The vigabatrin used alone may be effective to
suppress spasms and correct EEG abnormalities. However, in
case of failure of vigabatrin, the combination of ACTH at dose
of 0.01–0.015 mg/kg/day (0.4–0.6 IU/kg/day) may be more effec-
tive [14, 15]. Other corticosteroids, such as high-dose oral
hydrocortisone or prednisolone may be associated with viga-
batrin for a variable duration depending on the case. [14]
Whatever the drug chosen, the effectiveness of treatment
should be assessed within 2 weeks following dose titration.
This efﬁciency is controlled by regular EEG. Other antiepileptic
drugs such as topiramate, felbamate, sodium valproate or
lamotrigine can be used in case of spasm resistant to previous
treatments, as well as some benzodiazepines [13, 16].
Infantile spasms in children with Down syndrome were
described in the literature as particularly sensitive to treat-
ment than children with cryptogenic infantile spasms. The
response rate was measured at 96% of cases treated with
hormonotherapy (adrenocorticotrophic hormone or corticos-
teroids), 85% of cases treated with vigabatrin, and 73% of
cases treated with conventional antiepileptic drugs [2, 17,
18]. In our patient, Phenobarbital was temporarily effective
with a complete resolution of clinical spasms during the
ﬁrst two years. In our protocol Phenobarbital is the ﬁrst-line
treatment pending the results of the EEG. However,
the recurring spasms at the age of two years were treated
using the combination of sodium valproate with hydrocorti-
sone. This therapy was effective with good control of clinical
spasms without recurrence until the age of 7 years.
Despite early diagnosis and rapid initiation of effective
treatment, West syndrome is still associated with a poor long-
term prognosis. After an initial response, 12–57% of children
relapse within 6 months. Thereafter, spasms tend to disappear
before 5 years of age, but relapses are possible, as in our
patient. The long-term follow-up showed that 60% of the
children had drug-resistant epilepsy and that 75% of the
children had a delay in their psychomotor development [18,
19]. It is generally accepted that children with West syndrome
who have evidence of pre-existing developmental delay or
neurological abnormalities have a worse prognosis with
a poorer response to treatment and less favorable develop-
mental outcome [4]. However, children with Down syndrome
and West syndrome seem to have a better prognosis compa-
red to other patients with symptomatic infantile spasms with
a better control of clinical spasms, and early initiation of
appropriate treatment may contribute to the prevention of
late seizure development and better developmental outcome
[1, 2, 20].
Conﬂicting results have been published regarding the role
of diagnostic delay and/or treatment lag in the outcome of
infantile spasms [9]. It was reported in a study that in
children with Down syndrome, a time less than 2 months
prior to diagnosis of infantile spasms is associated with rapid
control of spasms and better psychomotor development [17],
while another study including infants with cryptogenic infan-
tile spasms reported that a delay less than one month indiagnosing infantile spasms was important for the outcome
[21]. Recently, it has been shown that the response to
treatment was signiﬁcantly better when treatment was
initiated less than 6 weeks after the diagnosis of infantile
spasms [10]. These results suggest the importance of early
diagnosis and rapid treatment to improve long-term progno-
sis of infantile spasms in children with Down syndrome.
Conclusion
This case study leads us to conclude that the initiation of
Phenobarbital therapy is not the adequate treatment for
patients with Down syndrome associated with infantile
spasms and psychomotor development delay. In the short-
term, this treatment was effective immediately with a good
clinical control of seizures. But in long-term, we observed an
unfavorable progression with persistence of hypsarrhythmia
on EEG and severely impaired psychomotor development.
The better knowledge about this association by physicians
and parents would reduce the time to diagnosis and delay
to treatment in order to optimize psychomotor development
and improve the quality of life of these children.
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